Literature DB >> 35435447

Algorithm of the major and minor diagnostic criteria for active myopic choroidal neovascularization.

Paolo Milani1, Marco Mazzola2, Mario Cigada2, Amedeo Massacesi2, Marco Setaccioli2, Stefania Moschini2, Stefano Ciaccia2, Fabrizio Scotti2, Elena Mantovani2, Davide Soranna3, Antonella Zambon3,4, Fulvio Bergamini2.   

Abstract

PURPOSE: To propose an algorithm of the major and minor diagnostic criteria for macular myopic choroidal neovascularization (mCNV).
METHODS: This single-center, retrospective, cross-sectional study was based in Istituto Auxologico Italiano, Milan, Italy. Two authors evaluated the clinical and imaging parameters of eyes with high myopia (spherical equivalent of -6D or less) and suspected to have naïve, recurrent, or inactive mCNV. Recordings of the eyes that met the inclusion criteria were then independently evaluated by two other senior retinal specialists. Fluorescein angiography (FA), spectral domain optical coherence tomography (SD-OCT), and OCT angiography were used for multimodal imaging.
RESULTS: One-hundred and twenty-two eyes (n = 107; 39 men, 68 women) were included in the study. The mean patient age was 66 years (range, 22-89 years). There were 83 and 39 eyes in the active mCNV and control groups, respectively. The best diagnostic algorithm had positive- and negative-predictive values of 89% and 85%, respectively, and was based on four criteria: leakage/staining on FA, retinal thickening, fuzzy area on SD-OCT, and recent metamorphopsia. When excluding FA-derived findings, retinal pigment epithelium (RPE) features played a diagnostic role in 33 eyes (27%). Twenty-seven eyes with active mCNV (32%) did not have the fuzzy area. Taken singularly, no clinical or imaging parameter had both sensitivity and specificity greater than 78%. Matching of 2 or 3 biomarkers did not yield a sensitivity or specificity greater than 79%. Sensitivities and specificities ≥ 90% were found in ten criteria combinations that included four to five biomarkers. The most frequent were metamorphopsia, fuzzy area, retinal thickening, and leakage. Less frequently, they included hemorrhage, staining, and RPE features such as elevation, flattening, and focal interruption. For all the parameters, the agreement between the investigators was good (Cohen k ≥ 0.66), being the lowest when detecting the ELM interruption within the lesion.
CONCLUSIONS: A combination of at least four clinical and biological markers yielded the highest positive- and negative-predictive values. More ("major") and less ("minor") frequent diagnostic criteria are proposed.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Diagnostic algorithm; Myopic CNV; Sensitivity; Specificity

Mesh:

Year:  2022        PMID: 35435447     DOI: 10.1007/s00417-022-05599-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  21 in total

1.  Utility of the 'fuzzy area' for active myopic choroidal neovascularization detection by spectral-domain optical coherence tomography.

Authors:  Giuseppe Casalino; Ugo Introini; Giuseppe Querques; Francesco Bandello
Journal:  Ophthalmologica       Date:  2014-11-28       Impact factor: 3.250

2.  Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography.

Authors:  Dong Hyun Lee; Hyun Goo Kang; Sung Chul Lee; Min Kim
Journal:  Br J Ophthalmol       Date:  2017-06-09       Impact factor: 4.638

3.  Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: correlation with activity.

Authors:  Xiaoyan Ding; Zongyi Zhan; Limei Sun; Yu Yang; Songshan Li; Aiyuan Zhang; Xiaoling Luo; Lin Lu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-07       Impact factor: 3.117

4.  Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization.

Authors:  Nicolas Leveziel; Violaine Caillaux; Sylvie Bastuji-Garin; Mathieu Zmuda; Eric H Souied
Journal:  Am J Ophthalmol       Date:  2013-01-23       Impact factor: 5.258

5.  Sensitivity of fluorescein angiography alone or with SD-OCT for the diagnosis of myopic choroidal neovascularization.

Authors:  Paolo Milani; Amedeo Massacesi; Marco Setaccioli; Stefania Moschini; Elena Mantovani; Stefano Ciaccia; Fulvio Bergamini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-26       Impact factor: 3.117

6.  Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Francesco Romano; Francesco Bandello
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

7.  CORRESPONDENCE OF LEAKAGE ON FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY PARAMETERS IN DIAGNOSIS AND MONITORING OF MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH BEVACIZUMAB.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Francesco Bandello
Journal:  Retina       Date:  2016-01       Impact factor: 4.256

Review 8.  Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.

Authors:  Tien Y Wong; Alberto Ferreira; Rowena Hughes; Gemma Carter; Paul Mitchell
Journal:  Am J Ophthalmol       Date:  2013-10-05       Impact factor: 5.258

Review 9.  Choroidal neovascularization in pathological myopia.

Authors:  Kumari Neelam; Chiu Ming Gemmy Cheung; Kyoko Ohno-Matsui; Timothy Y Y Lai; Tien Y Wong
Journal:  Prog Retin Eye Res       Date:  2012-04-28       Impact factor: 21.198

10.  ASSESSING THE ACTIVITY OF MYOPIC CHOROIDAL NEOVASCULARIZATION: Comparison Between Optical Coherence Tomography Angiography and Dye Angiography.

Authors:  Songshan Li; Limei Sun; Xiujuan Zhao; Sijian Huang; Xiaoling Luo; Aiyuan Zhang; Chonglin Chen; Zhirong Wang; Chengxi Liu; Xiaoyan Ding
Journal:  Retina       Date:  2020-09       Impact factor: 3.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.